Corporate News - 08 October 2021

Second Annual Hereditary Factor 10 Deficiency Awareness Day Kicks Off October 10

Download PDF

08 October 2021

To encourage education and awareness around Hereditary Factor X Deficiency

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, is proud to partner with the National Hemophilia Foundation in recognizing the second Hereditary Factor X (10) Deficiency Awareness Day on October 10, 2021. This day helps bring a very rare bleeding disorder to the forefront of people’s minds, including the patients it impacts, the challenges they face, and the treatments that might help.

About one in a million people have hereditary factor X deficiency, which causes unusual or excessive bleeding or bruising, heavy menstrual bleeding in women, painful or swollen joints, nose bleeds, and bleeding gums. Serious bleeding in the brain or stomach is also possible. Because the symptoms are so varied, patients may suffer for years before being diagnosed. Thankfully, a simple blood test can be done to determine whether someone has the disorder and can be treated with plasma-based treatments.  

Carly Magee, a mother of two children diagnosed with hereditary factor x deficiency, says it best. “Awareness and accurate diagnosis are essential to living a full, happy and healthy life with hereditary factor X deficiency. Using correct medication, educating and advocating for oneself or a child is key to protection from possible debilitating consequences of the disease.”

"After seeing the success of last year’s inaugural Hereditary Factor x Awareness Day, we knew we had to continue our work to raise awareness around hereditary factor X deficiency for those living with the disorder and those yet to be diagnosed," notes Bob Rossilli, US President and Chief Commercial Officer, Global Business for BPL. "We hope this day as well as ongoing efforts throughout the year help generate greater awareness of the signs and symptoms of hereditary factor X deficiency."  

“When living with a condition as rare as Hereditary Factor X Deficiency, it is easy to feel alone – but a day such as this reminds us that we are never alone,” said Dr. Leonard A. Valentino, a hematologist and CEO and President of the National Hemophilia Foundation. “This day is an important opportunity to raise our voices to bring awareness to Hereditary Factor X Deficiency and the amazing individuals and families living with this condition. NHF is grateful to partner with BPL in celebrating this cause.” 

About Bio Products Laboratory (BPL)

Recognizing the power of plasma and with many years of experience in the industry, BPL supplies high-quality plasma derived medicines to meet the needs of clinicians, patients and customers globally. Headquartered in the United Kingdom and with plasma collection centers across the United States, we are dedicated to producing medicines for the treatment of immune deficiencies, bleeding disorders and infectious diseases as well for critical care. BPL invests in the latest R&D, technology and manufacturing methods, and continuously adapts to ensure that we continue to serve all our stakeholders effectively. For more information visit http://www.bplgroup.com or https://www.bpl-us.com/

BPL consists of two operating divisions — BPL Plasma and BPL Therapeutics. BPL Plasma,

headquartered in Austin, Texas and operating in the USA, collects plasma from donors, in around 26 centers across the US. BPL Plasma employs over 900 staff, to support the needs of donors and to ensure high-quality plasma collection in all their centers. Plasma collection is regulated by both FDA and MHRA, and BPL Plasma follow industry guidelines. BPL Plasma operates clean and safe plasma facilities, staffed with trained personnel, dedicated to supporting donors through the process that leads to the donation of plasma. Plasma is shipped to the headquarters of BPL Therapeutics in Elstree, United Kingdom. The plasma is fractionated, purified, and filled through the efforts of our over 1,000 employees involved in production, quality, R&D, commercial, customer services and administrative activities. BPL’s plasma derived medicines are commercially available in the UK, USA and 30 plus other countries around the world through our network of local affiliates and distribution partners.

About Bio Products Laboratory USA (BPL USA)

BPL USA, headquartered in Durham, NC, is dedicated to delivering transformative therapies to patients in the areas of Immunology, rare bleeding disorders, and critical care. In addition to five currently available specialty medicines in the US market, BPL is also investing in the development of a robust pipeline of future product candidates for patients with rare and orphan diseases. Since receiving its first US FDA approval in 2009, BPL has proudly built a strong culture and reputation as an industry leader with specialty pharmacies, healthcare professionals, and patient advocacy organizations. BPL USA is part of a global company, Bio Products Laboratory, which boasts a vibrant 60-year heritage in plasma research, technology, and manufacturing. For more information about BPL in the United States, please visit www.bpl-us.com.